Boehringer’s Pradaxa Increases Risk of Heart Attack, Study Shows
This article is for subscribers only.
Boehringer Ingelheim GmbH’s anti-coagulant Pradaxa increases a patient’s risk of heart attack or severe chest pain, according to a review of studies conducted on the drug.
An analysis of seven clinical trials found that it was “significantly associated with a higher risk” of heart attacks and acute coronary syndrome, or ACS, a designation that includes heart attacks and chest pain, researchers wrote in a report published today in the Archives of Internal Medicine.